On August 20, 2018, the Federal Court dismissed Valeant's PMNOC application regarding Ranbaxy's bupropion extended-release tablets (Valeant's WELLBUTRIN XL) and Patent No. 2,524,300. Justice McVeigh held that Ranbaxy's allegation of non-infringement was justified: Valeant Canada LP v Ranbaxy Pharmaceuticals Canada Inc., 2018 FC 847. Justice McVeigh found that "permeation enhancer" in the amount of "about 20% to about 40% of the moisture barrier dry weight" is an essential element, construed "permeation enhancer" to exclude polyethylene glycol and triethyl citrate, and construed "about" to mean a range of plus or minus 10%. Therefore, the amount of permeation enhancer in the Ranbaxy formulation was outside the scope of the range claimed and Ranbaxy's allegation of non-infringement was found justified.
Related Publications & Articles
-
Federal Court of Appeal affirms paliperidone palmitate claims are not unpatentable methods of medical treatment
On February 1, 2024, the Federal Court of Appeal (FCA) dismissed Pharmascience’s appeal. Per the FCA, whether a claimed dosing regimen is an unpatentable method of medical treatment cannot be based ex...Read More -
Federal Court of Appeal dismisses appeal of SPRAVATO “innovative drug” decision
On November 10, 2021, the Minister of Health refused to reassess its decision that Janssen’s esketamine hydrochloride product (SPRAVATO) was not an “innovative drug” and therefore not entitled to data...Read More -
Federal Court finds patent for concentrated methotrexate solutions obvious
On March 26, 2024, the Federal Court dismissed Medexus and Medac’s action for patent infringement of Canadian Patent No 2,659,662, finding the asserted claims invalid for obviousness: Medexus Pharmace...Read More